- Home
- INTS vs SRZN Comparison
INTS vs SRZN Comparison
Compare INTS & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- SRZN
- Stock Information
- Founded
- INTS 2012
- SRZN 2015
- Country
- INTS United States
- SRZN United States
- Employees
- INTS N/A
- SRZN N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- INTS Health Care
- SRZN Health Care
- Exchange
- INTS Nasdaq
- SRZN Nasdaq
- Market Cap
- INTS 35.3M
- SRZN 38.1M
- IPO Year
- INTS 2023
- SRZN N/A
- Fundamental
- Price
- INTS $2.33
- SRZN $11.89
- Analyst Decision
- INTS Strong Buy
- SRZN Strong Buy
- Analyst Count
- INTS 3
- SRZN 2
- Target Price
- INTS $8.50
- SRZN $38.50
- AVG Volume (30 Days)
- INTS 18.1K
- SRZN 12.9K
- Earning Date
- INTS 03-21-2025
- SRZN 05-07-2025
- Dividend Yield
- INTS N/A
- SRZN N/A
- EPS Growth
- INTS N/A
- SRZN N/A
- EPS
- INTS N/A
- SRZN N/A
- Revenue
- INTS N/A
- SRZN $10,000,000.00
- Revenue This Year
- INTS N/A
- SRZN N/A
- Revenue Next Year
- INTS N/A
- SRZN N/A
- P/E Ratio
- INTS N/A
- SRZN N/A
- Revenue Growth
- INTS N/A
- SRZN N/A
- 52 Week Low
- INTS $1.50
- SRZN $6.00
- 52 Week High
- INTS $5.78
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- INTS 53.36
- SRZN 53.98
- Support Level
- INTS $2.17
- SRZN $11.11
- Resistance Level
- INTS $2.43
- SRZN $12.00
- Average True Range (ATR)
- INTS 0.20
- SRZN 0.73
- MACD
- INTS 0.01
- SRZN 0.07
- Stochastic Oscillator
- INTS 73.08
- SRZN 92.37
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).